Anti-GAD antibody-positive fulminant type 1 diabetes developed following SARS-CoV-2 vaccination.

IF 1.3 Q4 ENDOCRINOLOGY & METABOLISM

Diabetology International Pub Date : 2023-07-31 eCollection Date: 2023-10-01 DOI:10.1007/s13340-023-00648-8

Tomohito Izumi, Hironobu Takahashi, Hironori Takahashi

{"title":"Anti-GAD antibody-positive fulminant type 1 diabetes developed following SARS-CoV-2 vaccination.","authors":"Tomohito Izumi, Hironobu Takahashi, Hironori Takahashi","doi":"10.1007/s13340-023-00648-8","DOIUrl":null,"url":null,"abstract":"<p><p>Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been used worldwide since the 2020 coronavirus pandemic. However, several negative side-effects of these vaccines have been reported. Herein, we present a case of a patient with fulminant type 1 diabetes that developed shortly after administration of the SARS-CoV-2 vaccine. A 47-year-old man with no medical history presented with hyperglycemia-related symptoms shortly after receiving the third messenger ribonucleic acid SARS-CoV-2 vaccine. Based on hyperglycemia, diabetic ketoacidosis at onset, relatively low hemoglobin A1c levels, and complete depletion of endogenous insulin secretion, the patient was diagnosed with fulminant type 1 diabetes and insulin therapy was initiated. Through human leukocyte antigen genotyping, the disease-susceptible alleles for type 1 diabetes, DRB1*04:05 and DQB1*04:01, were identified. The patient tested positive for serum anti-glutamic acid decarboxylase antibodies, which are normally negative for fulminant type 1 diabetes, implying that immunomodulation triggered by SARS-CoV-2 vaccination influenced the onset of type 1 diabetes.</p>","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2023-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10533421/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetology International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13340-023-00648-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been used worldwide since the 2020 coronavirus pandemic. However, several negative side-effects of these vaccines have been reported. Herein, we present a case of a patient with fulminant type 1 diabetes that developed shortly after administration of the SARS-CoV-2 vaccine. A 47-year-old man with no medical history presented with hyperglycemia-related symptoms shortly after receiving the third messenger ribonucleic acid SARS-CoV-2 vaccine. Based on hyperglycemia, diabetic ketoacidosis at onset, relatively low hemoglobin A1c levels, and complete depletion of endogenous insulin secretion, the patient was diagnosed with fulminant type 1 diabetes and insulin therapy was initiated. Through human leukocyte antigen genotyping, the disease-susceptible alleles for type 1 diabetes, DRB1*04:05 and DQB1*04:01, were identified. The patient tested positive for serum anti-glutamic acid decarboxylase antibodies, which are normally negative for fulminant type 1 diabetes, implying that immunomodulation triggered by SARS-CoV-2 vaccination influenced the onset of type 1 diabetes.

查看原文本刊更多论文

接种严重急性呼吸系统综合征冠状病毒2型疫苗后出现抗GAD抗体阳性的暴发型1型糖尿病。

自2020年冠状病毒大流行以来，针对严重急性呼吸综合征冠状病毒2型（严重急性呼吸系统综合征冠状病毒）的疫苗已在全球范围内使用。然而，据报道，这些疫苗有几种负面副作用。在此，我们介绍了一例在接种严重急性呼吸系统综合征冠状病毒2型疫苗后不久出现的暴发性1型糖尿病患者。一名无病史的47岁男子在接种第三种信使核糖核酸严重急性呼吸系统综合征冠状病毒2型疫苗后不久出现高血糖相关症状。基于高血糖、糖尿病酮症酸中毒、血红蛋白A1c水平相对较低以及内源性胰岛素分泌完全耗尽，患者被诊断为暴发性1型糖尿病，并开始胰岛素治疗。通过人类白细胞抗原基因分型，确定了1型糖尿病的易感等位基因DRB1*04:05和DQB1*04:0.1。该患者的血清抗谷氨酸脱羧酶抗体检测呈阳性，通常对暴发性1型糖尿病呈阴性，这意味着严重急性呼吸系统综合征冠状病毒2型疫苗引发的免疫调节影响了1型糖尿病的发病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetology International ENDOCRINOLOGY & METABOLISM-

CiteScore

3.90

自引率

4.50%

发文量

期刊介绍： Diabetology International, the official journal of the Japan Diabetes Society, publishes original research articles about experimental research and clinical studies in diabetes and related areas. The journal also presents editorials, reviews, commentaries, reports of expert committees, and case reports on any aspect of diabetes. Diabetology International welcomes submissions from researchers, clinicians, and health professionals throughout the world who are interested in research, treatment, and care of patients with diabetes. All manuscripts are peer-reviewed to assure that high-quality information in the field of diabetes is made available to readers. Manuscripts are reviewed with due respect for the author''s confidentiality. At the same time, reviewers also have rights to confidentiality, which are respected by the editors. The journal follows a single-blind review procedure, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous. Single-blind peer review is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.